Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.53 |
| ▸ | TUBB | P07437 | 1/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533227 | 1.00 | KDM4E (0.56) | KDM4EGAAPDE3BPDE3AMEN1 | |
| SCHEMBL11553365 | 0.88 | ENPP1 (0.55) | KDM4EGAAPDE3BPDE3AMEN1 | |
| SCHEMBL3427577 | 0.88 | KDM4E (0.45) | KDM4EGAAPDE3BPDE3AMEN1 | |
| SCHEMBL6128121 | 0.81 | KDM4E (0.62) | KDM4EGAAPDE3BPDE3AMEN1 | |
| SCHEMBL14072478 | 0.80 | KDM4E (0.56) | KDM4EGAAPDE3BPDE3AMEN1 | |
| SCHEMBL29900596 | 0.80 | KDM4E (0.67) | KDM4EGAAPDE3BPDE3ATUBB4A | |
| SCHEMBL2722306 | 0.80 | KDM4E (0.67) | KDM4EGAAPDE3BPDE3ATUBB4A | |
| SCHEMBL6118802 | 0.78 | TNKS (0.63) | KDM4EMEN1KMT2AHTTTUBB4A | |
| SCHEMBL21524692 | 0.78 | KDM4E (0.53) | KDM4EGAAPDE3BPDE3AMEN1 | |
| SCHEMBL4980044 | 0.78 | PDE5A (0.45) | KDM4EPDE3BPDE3AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113896762-B | Liquid phase synthesis method of biotin tripeptide-1 | 浙江湃肽生物有限公司深圳分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-113896762-A | Liquid phase synthesis method of biotin tripeptide-1 | 浙江湃肽生物有限公司深圳分公司 | 2022-01-07 | — | — | CN | claimed |
| CN-1894234-A | Dipeptidyl peptidase inhibitors | SYRRX INC (JP) | 2007-01-10 | — | — | CN | claimed |
| EP-1608317-A4 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-12-27 | — | — | EP | claimed |
| EP-1608317-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | claimed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | claimed |
| US-20240262822-A1 | WDR5 INHIBITORS AND MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | disclosed |
| EP-4334305-A1 | WDR5 INHIBITORS AND MODULATORS | Vanderbilt University (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023287730-A1 | TRICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287730-A1 | TRICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022236101-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-113896762-B | Liquid phase synthesis method of biotin tripeptide-1 | 浙江湃肽生物有限公司深圳分公司 | 2022-03-29 | — | — | CN | disclosed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-1363899-A1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-26 | — | — | EP | disclosed |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | disclosed |
| WO-2002053558-A1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | F.HOFFMAN-LA ROCHE AG (CH) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | KDM4E 2328/4885GAA 154/4885PDE3B 229/4885 |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | KDM4E 3553/4885GAA 2623/4885PDE3B 511/4885 |
| US-20240262822-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | KDM4E 353/4885GAA 3973/4885PDE3B 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.